 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Rajesh Agarwal and Ram Raj Prasad.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.810 |
|
|
|
-
Prasad RR, Mishra N, Kant R, Fox JT, Shoemaker RH, Agarwal C, Raina K, Agarwal R. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis. Mol Carcinog. 2024 Jun; 63(6):1188-1204.
Score: 0.914
-
Prasad RR, Raina K, Mishra N, Tomar MS, Kumar R, Palmer AE, Maroni P, Agarwal R. Stage-specific differential expression of zinc transporter SLC30A and SLC39A family proteins during prostate tumorigenesis. Mol Carcinog. 2022 05; 61(5):454-471.
Score: 0.787
-
Prasad RR, Paudel S, Raina K, Agarwal R. Silibinin and non-melanoma skin cancers. J Tradit Complement Med. 2020 May; 10(3):236-244.
Score: 0.687
-
Raina K, Kandhari K, Kant R, Prasad RR, Mishra N, Maurya AK, Fox JT, Sei S, Shoemaker RH, Bosland MC, Maroni P, Agarwal C, Agarwal R. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against TMPRSS2-ERG (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer. Cancers (Basel). 2023 Oct 19; 15(20).
Score: 0.222
-
Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 07; 61(7):717-734.
Score: 0.200
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|